Kotaro Shide

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2416549/publications.pdf

Version: 2024-02-01

93 papers	2,496 citations	361413 20 h-index	206112 48 g-index

102 all docs	102 docs citations	102 times ranked	4478 citing authors

#	Article	IF	Citations
1	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	21.4	659
2	Aberrant PD-L1 expression through 3â€²-UTR disruption in multiple cancers. Nature, 2016, 534, 402-406.	27.8	536
3	Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia, 2008, 22, 87-95.	7.2	158
4	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	1.4	124
5	TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia, 2012, 26, 2216-2223.	7.2	73
6	Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood, 2015, 125, 304-315.	1.4	67
7	Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia, 2017, 31, 1136-1144.	7.2	62
8	Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leukemia Research, 2005, 29, 761-769.	0.8	53
9	Signal Transducers and Activators of Transcription 3 Augments the Transcriptional Activity of CCAAT/Enhancer-binding Protein Î± in Granulocyte Colony-stimulating Factor Signaling Pathway. Journal of Biological Chemistry, 2005, 280, 12621-12629.	3.4	48
10	JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. British Journal of Haematology, 2010, 150, 334-344.	2.5	46
11	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	1.4	44
12	Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e29-e29.	6.2	38
13	The Effect of Anabolic Steroids on Anemia in Myelofibrosis with Myeloid Metaplasia: Retrospective Analysis of 39 Patients in Japan. International Journal of Hematology, 2007, 85, 338-343.	1.6	36
14	Elevated HIF-1Î± expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leukemia Research, 2012, 36, e122-e124.	0.8	34
15	Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils. Nature Communications, 2021, 12, 6177.	12.8	30
16	The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan. European Journal of Haematology, 2009, 83, 328-333.	2.2	27
17	Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice. Leukemia, 2021, 35, 454-467.	7.2	27
18	Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer Journal, 2014, 4, e174-e174.	6.2	24

#	Article	IF	Citations
19	p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochemical and Biophysical Research Communications, 2009, 383, 411-416.	2.1	23
20	R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm. Blood, 2011, 117, 6866-6875.	1.4	23
21	Vitamin D receptorâ€“mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. Blood, 2019, 133, 1619-1629.	1.4	21
22	TET2 Mutation in Adult T-Cell Leukemia/Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2015, 55, 145-149.	0.8	19
23	Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. International Journal of Hematology, 2010, 92, 320-325.	1.6	18
24	Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Advances, 2017, 1, 1001-1015.	5.2	16
25	<i>TET2</i> mutation in diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 56, 145-149.	0.8	16
26	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. BMC Cancer, 2020, 20, 5.	2.6	16
27	Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis. Blood Cancer Journal, 2019, 9, 42.	6.2	15
28	Potentiated activation of VLA-4 and VLA-5 accelerates proplatelet-like formation. Annals of Hematology, 2012, 91, 1633-1643.	1.8	14
29	Effects of mogamulizumab in adult Tâ€cell leukemia/lymphoma in clinical practice. European Journal of Haematology, 2017, 98, 501-507.	2.2	14
30	Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. International Journal of Hematology, 2018, 108, 411-415.	1.6	14
31	Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan. International Journal of Hematology, 2018, 107, 681-688.	1.6	13
32	Tyrosine kinase 2 interacts with the proapoptotic protein Siva-1 and augments its apoptotic functions. Biochemical and Biophysical Research Communications, 2010, 400, 252-257.	2.1	12
33	Essential thrombocytosis attributed to JAK2-T875N germline mutation. International Journal of Hematology, 2019, 110, 584-590.	1.6	11
34	Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leukemia Research, 2007, 31, 1077-1084.	0.8	10
35	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. Blood Cancer Discovery, 2021, 2, 450-467.	5.0	10
36	Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood, 2020, 136, 106-118.	1.4	10

#	Article	IF	Citations
37	Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. Haematologica, 2021, 106, 532-542.	3.5	9
38	Dynamics of Epstein-Barr virus load in pyothorax-associated lymphoma. Journal of Medical Virology, 2003, 70, 137-140.	5.0	8
39	Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. International Journal of Hematology, 2016, 103, 423-428.	1.6	8
40	Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World Journal of Hepatology, 2017, 9, 1340-1345.	2.0	8
41	Acute myeloid leukemia in clinical practice: a retrospective population-based cohort study in Miyazaki Prefecture, Japan. International Journal of Hematology, 2012, 96, 342-349.	1.6	7
42	Outcome of allogeneic hematopoietic cell transplantation in patients with adult <scp>T</scp>â€cell leukemia. Hematological Oncology, 2018, 36, 651-655.	1.7	7
43	The role of driver mutations in myeloproliferative neoplasms: insights from mouse models. International Journal of Hematology, 2020, 111, 206-216.	1.6	7
44	Frequent Activating Somatic Alterations in T-Cell Receptor / NF-Îºb Signaling in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 113-113.	1.4	7
45	A Novel Mutation in the Juxtamembrane Intracellular Sequence of the Granulocyte Colony-Stimulating Factor (G-CSF) Receptor Gene in a Patient with Severe Congenital Neutropenia Augments G-CSF Proliferation Activity but Not through the MAP Kinase Cascade. International Journal of Hematology, 2005, 82, 28-34.	1.6	6
46	Chronic thrombopoietin overexpression induces mesangioproliferative glomerulopathy in mice. American Journal of Hematology, 2007, 82, 802-806.	4.1	6
47	Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. International Journal of Clinical Oncology, 2012, 17, 336-340.	2.2	6
48	Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult Tâ€cell leukemia/lymphoma. European Journal of Haematology, 2021, 106, 398-407.	2.2	6
49	Calreticulin mutations in myeloproliferative neoplasms. International Review of Cell and Molecular Biology, 2021, 365, 179-226.	3.2	6
50	NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant. Blood, 2010, 116, 4106-4106.	1.4	5
51	Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan. Journal of Clinical Medicine, 2021, 10, 105.	2.4	5
52	Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy. Internal Medicine, 2015, 54, 1455-1459.	0.7	4
53	Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms. Genomics Data, 2015, 4, 102-108.	1.3	4
54	Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018. Blood, 2010, 116, 4107-4107.	1.4	4

#	Article	IF	Citations
55	Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 348-353.	1.3	3
56	Efficacy of R723, a Potent and Selective JAK2 Inhibitor, in JAK2V617F-Induced Murine MPD Model.. Blood, 2009, 114, 3897-3897.	1.4	3
57	Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation. Blood, 2018, 132, 97-97.	1.4	2
58	NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count. Blood, 2013, 122, 3847-3847.	1.4	2
59	Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma. Viruses, 2022, 14, 710.	3.3	2
60	Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations. Annals of Laboratory Medicine, 2017, 37, 159-161.	2.5	1
61	Abstract 12873: Clonal Hematopoiesis With JAK2V617F Promotes Pulmonary Hypertension Through ALK1. Circulation, 2020, 142, .	1.6	1
62	Therapies Targeting the MAPK Pathway Improve Bone Marrow (BM) Fibrosis Induced By JAK2V617F. Blood, 2014, 124, 162-162.	1.4	1
63	Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma. Blood, 2014, 124, 75-75.	1.4	1
64	Mogamulizumab for ATLL in Clinical Practice. Blood, 2016, 128, 2998-2998.	1.4	1
65	Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. Anticancer Research, 2017, 37, 3841-3847.	1.1	1
66	CARD11 Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ. Blood, 2020, 136, 17-18.	1.4	1
67	Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas. Blood, 2020, 136, 3-4.	1.4	1
68	Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly. Tohoku Journal of Experimental Medicine, 2022, 256, 119-125.	1.2	1
69	Fibrocytes in primary myelofibrosis. Oncotarget, 2021, 12, 2101-2103.	1.8	0
70	Tyrosine Kinase 2 (Tyk2) Interacts with and Phosphorylates Siva-1, and Auguments the Apoptotic Effect Induced by Siva-1.. Blood, 2006, 108, 1726-1726.	1.4	0
71	Tyk2 Mutation Homologous to V617F Jak2 Is Not Found in Essential Thrombocythaemia, Although It Induces Constitutive Signaling and Growth Factor Independence.. Blood, 2006, 108, 4888-4888.	1.4	0
72	Expression of V617F JAK2 in Mice Leads to MPD Mimicking Human ET, Idiopahtic Myelofibrosis, and PV.. Blood, 2007, 110, 2531-2531.	1.4	0

#	Article	IF	Citations
73	Elevated Leukocyte Alkaline Phosphatase Scores Induced by Jak2 V617F Mutation. Blood, 2008, 112, 5244-5244.	1.4	0
74	JAK2V617F Mutation Selectively Exerts the STAT3 Pathway for Enhancing a Neutrophil Activation Marker.. Blood, 2009, 114, 1901-1901.	1.4	0
75	Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma.. Blood, 2009, 114, 1921-1921.	1.4	0
76	Potentiated Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation In Megakaryocytes.. Blood, 2010, 116, 2585-2585.	1.4	0
77	TET2 Is Essential for Survival in Mice, and Decreased TET2 Expression Enlarges HSC Compartment and Alters Cell Differentiation. Blood, 2011, 118, 2471-2471.	1.4	0
78	Impact Of TET2 Deficiency On MPN Harboring JAK2V617F Mutation. Blood, 2013, 122, 478-478.	1.4	0
79	Î±SMA+ Macrophages Skewed From Hematopoietic Stem Cells By Vitamin D3 Initiate Myelofibrosis and Subsequent Osteosclerosis. Blood, 2013, 122, 340-340.	1.4	0
80	Ezh2 Loss Accelerates JAK2V617F-Driven Primary Myelofibrosis. Blood, 2013, 122, 110-110.	1.4	0
81	Prognostic Factor, Including Relative Dose Intensity, For Adult T-Cell Leukemia/Lymphoma In Clinical Practice. Blood, 2013, 122, 1799-1799.	1.4	0
82	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. Blood, 2015, 126, 3882-3882.	1.4	0
83	Expression of HMGA2 Collaborates with JAK2V617F to Progress Myeloproliferative Neoplasms. Blood, 2015, 126, 482-482.	1.4	0
84	HMGA2 Orchestrates the Tumorgenesis of Myeloproliferative Neoplasms (MPN) in Corporation with JAK2V617F. Blood, 2016, 128, 796-796.	1.4	0
85	Physiological Expression of Calr Mutant Increases Cell Growth and Cytokine Independency in Human Cell Lines Expressing Mpl, and Develops Essential Thrombocythemia in Mice. Blood, 2016, 128, 954-954.	1.4	0
86	Mutant calreticulin causes essential thrombocythemia. Oncotarget, 2017, 8, 88251-88252.	1.8	0
87	TET2 Mutation Associated with Organ Infiltrations in ATLL. Blood, 2018, 132, 1345-1345.	1.4	0
88	Depletion of Neoplastic CD11b Positive Cells in Jak2V617F Mutant Mice Reduced Fibrocytes in Bone Marrow and Improved Myelofibrosis. Blood, 2019, 134, 310-310.	1.4	0
89	The Role of Calreticulin in Normal Hematopoiesis and Neoplastic Hematopoiesis of Myeloproliferative Neoplasms. Blood, 2019, 134, 309-309.	1.4	0
90	JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review. Leukemia Research Reports, 2020, 13, 100194.	0.4	0

#	Article	IF	Citations
91	Dissecting Multicellular Ecosystems of HTLV-1 Infection and ATL By Multi-Omics Single Cell Analysis. Blood, 2020, 136, 18-18.	1.4	0
92	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	1.4	0
93	Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma. Experimental Hematology, 2022, 111, 41-49.	0.4	0